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Principles of Chemotherapy and
Their Application to the
Management of Lymphosarcoma
T.L. Medinger, DVM*
W.B. Morrison, DVM**
Introduction
Most repons of treatment of lymphosarcoma
(LSA) in domestic animals have involved canine and
feline LSA. The disease in cats differs from that in
dogs in that feline LSA is caused by a contagious
retrovirus. Controversy has existed as to whether fe-
line leukemia virus (FeLV) positive cats with LSA
should be treated because of their danger to other
cats, or because of the controversial question of a
human health hazard. There has been no proven
danger to people, and 30% of cats with LSA are
FeLV negative. 1 Some owners elect chemotherapy
for their cats regardless of potential risks. As a result
of this increasing awareness of pet owners to the
potential benefits to be gained by chemotherapy,
the practicing veterinarian must be able to skillfully
administer chemotherapy to pets who have devel-
oped cancer.
The purpose of this paper is to describe the prin-
ciples of chemotherapy as currently understood and
to integrate these principles with the clinical
management of the most common malignant dis-
order of the cat; feline LSA. 2
Chemotherapy of the Cancer Patient -
General Principles
Interrelationships: Tumor, Host and Drug
The veterinarian, when utilizing cancer
chemotherapeutics, should always keep in mind the
interactions between the tumor, host, and drugs.
These interactions are: (a) disease, i.e., the effect(s)
of the tumor on the host; (b) therapy, the effect{s)
of the drug on the tumor; (c) toxicity, the effect(s)
of the drug on the host. The dominant factor or
factors in this relationship determine the fmal out-
come of the animal receiving cancer chemotherapy.
*Dr. Medinger is a 1986 graduate of the College of Veterinary
Medicine at Iowa State University.
**Dr. Morrison is an associate professor in the Department of
Veterinary Clinical Sciences at Iowa State University.
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For example, an excellent response to therapy en-
compasses remission of signs or symptoms of dis-
ease without the impairment of normal functions
of the host due to toxicity. The quality of survival,
determined by these interactions, is very imponant
to the client and veterinarian since euthanasia ex-
ists as an alternative.
Selection of Patient for Chemotherapy
Considerable care should be taken in the selec-
tion of cases suitable for chemotherapy so that
wonhwhile regressions are obtained in as many in-
stances as possible. Chemotherapy is the most suit-
able form of therapy for patients with tumors which
are not amenable to surgery or radiation therapy.
Thus, patients with disseminated tumors such as
leukemia, lymphosarcoma, multiple myeloma and
other hemopoietic tumors or patients with malig-
nant solid tumors which may have metastasized
should be considered for chemotherapy.3,4,s Car-
cinomas and sarcomas in which the majority of the
tumor has been destroyed by surgery, cryosurgery,
or radiotherapy but have high risks of recurrence
and /or metastases can also be candidates for
chemotherapy.4,6
In general, chemotherapeutic agents give the best
results when used to treat rapidly growing tumors,
and are much less effective when the tumor is grow-
ing slowly and contains many dividing cells. 3,7
Malignant cells in hemopoietic cancers have a very
high growth rate compared to solid tumors and nor-
mal tissues and are thus especially susceptible to an-
ticancer drugs. It is also thought that solid tumors
develop primary and secondary resistance to drugs
earlier than other neoplasms.6 In order to obtain
a complete cure it is essential that all the malig-
nant cells in the body be killed. The smaller the
number of malignant cells present, the greater is
the chance of obtaining a 100 % kill. Thus
chemotherapy should be statted as soon as possi-
ble and used as an adjunctive therapy to surgery
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and radiation therapy whenever possible. Another
fact which lends support to the debulking of tumors
prior to initiation of chemotherapy is that in the
center of large tumors drug penetration is low due
to the poor blood supply.
The effectiveness of chemotherapy in treating
tumors in animals cannot be accurately estimated
until a histological identification is made so that
the biological behavior of the tumor can be assessed.
However, chemotherapy is useful for those tumors
in which the results of surgery or radiation therapy
are poor as established by clinical trials. 3,5
Until recently, there has been considerable reluc-
tance to administer toxic drugs to patients appar-
ently clinically free of tumor after surgery or
radiotherapy. However, there is strong evidence that
some such patients are not free of malignant cells
and that aggressive chemotherapy before metastases
are clinically detectable increases the chances of sur-
vival. The problem is to identify those patients with
clinically undiscernable metastasis who would
benefit from adjunctive therapy. The development
of biochemical or immunological assays for the
presence of tumor cells would therefore be an im-
portant contribution to the control of tumors by
chemotherapy. Until such assays are developed the
selection of patients for adjuvant chemotherapy can
be based only on an estimation of the degree of
malignancy of the type of primary tumor involved.
Before any animal is selected to receive
chemotherapy, the clinician must be able to meet
the following standards in order to utilize
chemotherapeutic agents safely:
(1) Establish a histological diagnosis of malig-
nancy and a known sensitivity to antineo-
plastic drugs.
(2) Be familiar with the drugs and their poten-
tial toxicity.
(3) Use safe dosage schedules established for dogs
and cats.
(4) Be able to monitor toxicity at regular in-
tervals.
(5) Be able to evaluate an adequate response.
(6) Establish a willingness on the part of the
client to cooperate fully with the veterinar-
ian during a carefully planned therapy
program.
The decision to initiate therapy or select which
drugs may be best administered may be influenced
by the pre-treatment evaluation of the patient. A
complete p.istory should be taken to establish if any
previous therapy has been given or if there has been
any other recent illness which may influence the ef-
fectiveness of the drugs. A complete physical ex-
amination along with baseline hematological data
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such as complete blood counts, platelet counts, uri-
nalaysis and liver and kidney function tests are man-
datory. Other tests such as bone marrow
examination or special radiological procedures may
be needed to completely evaluate the extent of dis-
ease or underlying complications.
Cell Kinetics
A knowledge of the cell cycle or the prolifera-
tive state of the cell population is imponant for un-
derst~nding the cytotoxic effects of cancer
chemotherapy. The cell cycle can be defined as an
orderly sequence ofevents occurring during the time
interval between one cell division and the next di-
vision. 3 The cell cycle is divided into the following
phases: mitosis (M), postmitotic growth in which
RNA and protein synthesis occur prior to DNA syn-
thesis (G), resting or nonproliferative phase for
differentiated cells (Go), new DNA synthesis (S),
and RNA and protein synthesis prior to mitosis
(G2). Cell populations differ in relationship to DNA
snythesis and mitosis in that some cells continuously
move through the cell cycle; other cells leave the
cycle but can be induced to synthesize DNA and
divide by certain stimuli; and fmally, some cells will
leave the cycle permanently and will die without
further division.
Normal cells have four basic properties: (1) abil-
ity to proliferate; (2) capacity for self-renewal; (3)
ability to differentiate; and (4) sensitivity to regula-
tory mechanisms. 5 Malignant cells have the fust two
properties and differentiation may be present but
abnormal. The main difference between normal
and malignant cells is response to regulation; in
malignant cells this property is either greatly
reduced or completely absent. The ideal treatment
would bring about maximum normal cell survival
and minimal tumor cell recovery.
The response of cells to drugs depends on the
mechanism of action of the drug and the position
of the cell in the cell cycle. 3,5 Not only do drugs
kill at different stages of the cycle, but if a drug
can be used to arrest cells at one stage of the cycle,
a second drug killing at maximum effect at this
stage can then be instituted.4
Anticancer drugs can be divided into six classes
according to their mechanism of action. 3
1. Hormones were one of the first types of
chemotherapeutic agents to be used against
tumors but their mechanism of action is not yet
completely understood. It is thought that they
may act by interfering with cell membrane
receptors that stimulate growth.
2. The alkylating agents were the fust synthetic an-
43
titumor agents to be used. They are thought to
act by crosslinking cellular DNA by the forma-
tion of a covalent bond, thus impeding its ability
to act as a template for RNA or DNA synthesis.
3. The antimetabolites interfere with the biosyn-
thesis of nucleic acids by substituting for nor-
mal metabolites and by inhibiting normal en-
zymatic reactions.
4. Antibiotics are thought to bind nonspecifically
to cellular DNA and inhibit transcription.
s. Mitotic inhibitors destroy the mitotic spindle of
the cell and prevent cell division.
6. Miscellaneous drugs are those which act by a
combination of mechanisms or which do not act
in any of the ways described above or whose
mechanisms of action is at present unknown.
Expression of Drug Doses
The objective of chemotherapy is to dose to max-
imum efficacy with minimum toxicity. The utili-
zation of drugs and expression of their dosages on
a body weight basis (e.g., mg/kg) is a common
practice in veterinary and human medicine. In the
human adult, there may be justification for stan-
dardization of dosages of the majority of drugs by
this method. However, this has not proved to be
a valid practice in pediatrics nor with the use of an-
tineoplastic agents. The same may prove true for
other drugs which are now routinely given on a
sliding-dosage scale.
A comparison of the toxicity of anticancer agents
has been made in the mouse, rat, hamster, dog,
monkey, and human (Freireich et al., 1966). There
were large differences in the maximum tolerated
dose if it was based on mg/kg body weight, but
the dose was found to be approximately the same
in all species if based on surface area - mg/meter
squared (mg/M2).4 This method ensures adequate
dosing in small dogs and cats and precludes over-
dosing in large dogs.
The fate of systemically administered drugs de-
pends on many factors and may include the follow-
ing: route, dose, and speed of administration;
mechanism and distribution of intra -and/or ex-
tracellular uptake of the drug; presence of other
drugs or substances which interact or interfere; ex-
tent, rate, mechanism(s), and tissue(s) of
metabolism and excretion of the drug; total body
fluid and/ or blood volume; and others.8Thus, the
pharmacokinetics of most drugs depend on one or
more physiologic processes of the host.
The basal metabolic rate (BMR) perhaps best
reflects most of these physiologic functions in the
normal animal. But its determination is tedious and
is often impossible to obtain accurately and quick-
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lYe The BMR has been shown to be best approxi-
mately by the body surface area (BSA).8 The BSA
of an animal can be easily determined by the
formula:
Kx(W)%
A = 104
where A is the body surface area in square meters,
W is the body weight in grams and K is a constant
(10.0 for cats and 10.1 for dogs). In addition, the
dose gf a drug in mg/kg can be easily converted
to mg/M2 by the formula:
(Dose in mg/M2) = kf x (Dose in mg/kg)
where kf is a conversion factor given by the
formula:
(wt) 1/3 x102
kf = K
where wt is the body weight in kilograms and K
is the constant (10.0 for cats and 10.1 for dogs).
Conversion charts for directly determining the
BSA in M2 have been provided by others.3,4
Combination Therapy
It has been found that many chemotherapeutic
agents used alone can produce only limited remis-
sions. Combination chemotherapy, that is, when
several different drugs are used together (or in se-
quence), has proved to be more effective than sin-
gle drug therapy.l,3,5,9-11 Drugs to be used in
combination chemotherapy should have an exist-
ing proven effect - either crytostatic or cytotoxic
- against tumors when used alone, or should be
capable of arresting the neoplastic cell at a particu-
lar stage of the cell cycle when it is susceptible to
other drugs. Four basic principles underlie the de-
sign of combination chemotherapy protocols. These
are: (1) the fraction of tumor cells killed_by one drug
is independent of the fraction killed by another
drug; (2) drugs with different mechanisms of ac-
tion should be chosen so that the antitumor effects
will be additive; (3) since different classes of drugs
have different toxicities, the toxic effects will not
be additive and each drug can be used at its maxi-
mum dose and (4) use only drugs with known ac-
tivity against a specific neoplasm. 3,5,9,10 Drugs that
show some efficacy when used in certain species for
the treatment of LSA are vincristine, cyclophospha-
mide, L-asparaginase, doxorubicin HCL and pred-
nisone. Chlorambucil, antimetabolities including
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methotrexate and cytosine arabinoside,
6-mercaptopurine, and 6-thionguanine have been
advocated in combination protocols but have not
shown antitumor activity as single agents. Other
drugs have been used in drug-resistant or relapsed
LSA cases. These include dacarbazine, procarbazine,
CCNU, Cis-platinum, and bleomycin sulfate. At-
tempts to reinduce remission with these drugs have
been discouraging. 11 It should be noted that be-
cause of the eat's unique hepatic metabolism, not
all of these drugs can be used safely in this species.
Experimental tumor systems have shown that the
emergence of populations resistant to the individual
drugs can be delayed or suppressed if a combina-
tion of several drugs is used and therefore prolong
the time necessary for these cells to produce clini-
cally apparent disease.4,5 When the toxic effects of
chemotherapeutic agents used in a given protocol
do not overlap too greatly, it is possible to use
almost maximum doses of each individual drug
without greatly increasing toxicity.
Combination chemotherapy is most efficacious
when given in intensive intermittent courses rather
than in continuous low dose form. There tends to
be greater tumor cell death and much less im-
munosuppression. Intermittent, intensive
chemotherapy may augment the endogenous cel-
lular immune response to tumor cells during the
recovery period.
Toxicity and Complications
Most chemotherapeutic drugs are toxic to all
dividing cells and the distinction between therapeu-
tic and toxic doses is often very fine. Thus, the
difference in susceptibility between normal and
tumor cells governs the choice of drug, dose, and
effectiveness of chemotherapy. The toxic side ef-
fects may be slight: mild alopecia, anorexia, vomit-
ing and diarrhea may necessitate only a temporary
withdrawal of chemotherapy. Side effects such as
thrombocytopenia, leukopenia, anemia, and gas-
trointestinal bleeding are usually mild but in some
cases can be so severe that chemotherapy may have
to be discontinued permanently. 5 It is essential that
all animals receiving chemotherapy be monitored
frequently.
Monitoring should include a thorough physical
examination, complete blood cell count and platelet
count every 7 to 10 days. Serum enzyme levels and
renal function should be monitored as needed or
every several months. In no case should the total
white cell count be allowed to fall below
300d/mm3. 3,5 Transfusion facilities and antibiotics
should be available to suppon the patient in case
of severe bone marrow depression. If complete
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monitoring facilities are not available then
chemotherapy should be limited to the adminis-
tration of hormones where the risk of severe side
effects are low. The drug L-asparaginase could also
be used in this situation; keeping in mind that
anaphylaxis has been known to occur with its use.
It is very imponant for the veterinarian to
remember that once a drug (except methotrexate)
has been administered, there is nothing that can
neutralize its action or prevent serious delayed side
effects. A thorough explanation to the client about
potential side effects before the use of anticancer
drugs will help the client observe the patient at
home and detect the earliest signs of complications,
thus allowing early treatment.
Generally, the majority of the anticancer drugs
cause myelosuppression and immunosuppression
but a few of the drugs have unique toxic side ef-
fects. Cyclophosphamide and vincristine will be dis-
cussed later. With 5-fluorouracil bizzare central
nervous system reactions have been seen. The reac-
tions are characterized by apparent hallucinations,
hyperexcitability, fright, and severe personality
change. This drug is highly toxic to cats and should
not be given to cats under any circumstances.
Side effects indirectly related to the drugs are
those due to rapid tumor cell breakdown and can
lead to abnormal hepatic or renal function. Local
reactions such as pain, edema, inflammation, and
abscess formation or tissue necrosis can occur as the
tumor cells die and are eliminated from the body.
Toxic Side Affects of Agents Commonly used for
Therapy of Lymphorsarcoma
Vincnstine. This drug is a plant alkaloid. Its
mechanisms of action is related to an arrest of cell
division in metaphase. It appears to exhibit minimal
myelosuppression compared with other agents. A
peripheral neuropathy may occur at chronic, high
doses. This may manifest itself in any of several
ways; (1) a noticeable change in the animal's gait,
(2) constipation secondary to colonic atony, or (3)
voice changes due to laryngeal dysfunction. These
are uncommon but ususally reversible conditions.
Perivascular infiltration of the agent will cause se-
vere tissue inflammation and probable loss of local
venous access.
L-asparaginase. This drug is a bacterial enzyme
that (in some cases) exploits the inability of malig-
nant lymphoblasts to produce i-asparagine by des-
troying extracellular supplies of this essential amino
acid. Because normal cells can produce L-
asparagine, little to no host toxicity is produced by
this effect. However, bacterial cell products con-
taminating the agent can result in an anaphylactic
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reaction occurring in animals within either their fust
treatment exposure or after repeated exposure to L-
asparagine. Thus, clinicians administering L-
asparaginase to patients must be prepared to con-
trol potential allergic reactions.
Cyclophosphamide. This alkylating agent causes
damage to nucleic acids, interfering with DNA
replication and the transcription of RNA. The
drug's major toxic effects are to rapidly proliferat-
ing normal tissues such as bone marrow and intes-
tinal mucosa. Thus, leukopenia, thrombocytopenia,
vomiting and diarrhea are possible complications.
Most authors suggest temporarily decreasing or dis-
continuing the use of myelosuppressive drugs if the
pretreatment leukocyte count is below 3500 to 4000
cells/mm3• 1,9
In addition to these toxicities, cyclophosphamide
may produce hemorrhagic cystitis secondary to uri-
nary excretion of the drug's inactive metabolities.
The likelihood of this is probably directly related
to the length of time the metabolities remain in
the urinary bladder. An animal able and willing
to urinate and one that maintains a normal or in-
creased urine output (such as a patient being given
glucocorticoids) is thus less likely to develop a drug
related cystitis. Cats develop cyclosphamide induced
cystitis much less frequently than dogs.
Cytosine arabinoside. This drug is metabolized
to a necleoside analogue, acting as a competitive
inhibitor of DNA polymerase. It is considered to
be an antimetabolite drug. The major toxicities
from the agent are myelosuppression and intesti-
nal mucosal damage, which are similar to those oc-
curing with cyclophosphamide. Therefore, if the
two drugs are used in the same protocol, the clini-
cian and owner should be aware of the potential
for additive toxic effects.
Methotrexate. Also an antimetabolite, this drug
is one of the first folic acid inhibitors introduced
for antitumor therapy. It has potent toxic effects
similar to those of other antimetabolities, includ-
ing cytosine arabinoside.
Prednisone. In addition to their palliative
benefits in the animal with debilitating malignant
disease, corticosteroids are employed as lymphocy-
totoxic agents in patients with lymphoreticular
tumors. Prednisolone may be used instead in
equivalent dosages. In the high daily doses used,
several adverse effects are possible. These include
suppression of the hypothalamic-pituitary axis,
polyuria, polyphagia, and, like most the anticancer
drugs, immunosuppression. Alternate-dayadminis-
tration may decrease some of these complications.9
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Chemotherapeutic Protocols of the
Management of Lymphosarcoma
Once the decision is made that the patient is a
good candidate for chemotherapy, the initiation of
treatment is preceded by a discussion with the own-
er concerning prognosis and an estimate of costs,
both in time and money. In animals treated with
standard antitumor protocols, at least one fact is
clear: Patients that respond with a complete remis-
sion tend to live longer and enjoy a better quality
of life than those that fail to respond completely.
Thus, for example, cats with LSA originating in the
mediastinum, alimentary tract, or peripheral lymph
nodes (that is, forms that show a marked sensitiv-
ity to cytotoxic therapy) appear to have a better
prognosis than cats presenting with other forms,
such as primary leukemia or central nervous system
LSA.9 The median duration or remission reported
for cats responding to cytotoxic chemotherapy has
varied from 4 to 28 months, depending on the form
and stage of the disease.
Several specific protocols of tumor management
have been reported. 1,2,9
Tumor Resistance to Chemotherapy
The development in tumor cells of varying
degrees of resistance to drugs is one of the limiting
factors in tumor chemotherapy. If this phenome-
non did not exist many tumors could probably be
kept under control indefinitely by chemotherapy.
Unfortunately, however, resistance to drugs de-
velops in all tumors to varying degrees while nor-
mal cells which are sensitive to antitumor drugs do
not develop resistance. It is not known whether drug
resistant cells pre-exist in drug sensitive tumors or
whether resistant cells appear as the result of drug
induced mutations. Some of the most important
ways in which tumor cells may acquire resistance
are: (1) the development of alternative metabolic
pathways (sometimes seen with L-asparaginase); (2)
the development of repair mechanisms to correct
the damage done by the drug; (3) destruction of
the drug by the cell; (4) changes in the permeabil-
ity of the cell membrane; (5) tumor cells entering
the resting (G 0) phase of the cell cycle; and (6) de-
letion of cellular drug activation mechanisms. 3,5,6
Some tumors are naturally resistant to chemother-
apy. In many cases the reasons for this natural (as
opposed to acquired) resistance are unknown. In
other cases drug resistance is the result of the ana-
tomicallocation of the tumor. For example, most
chemotherapeutic agents cannot cross the blood-
brain barrier; thus primary or secondary metastatic
neoplasms in the central nervous system survive the
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intended actions of these drugs.
The development of drug resistant tumors can
be limited by the use of combination chemothera-
py. In addition to the additive antitumor effects
of combined drug therapy, some tumors become
more susceptible to one drug as they become more
resistant to another. 3 This phenomenon has been
observed in some animal tumors but is unfottunate-
Iy rather rare.
Summary
As pet owners become more knowledgeable
about the various options available to them con-
cerning their pet stricken with a neoplastic disease,
veterinarians must be able to respond and outline
a treatment regimen which is both efficacious and
economical. By utilizing the principles outlined in
this paper, the veterinarian will have a foundation
upon which to build according to the specific needs
and desires of his clientele.
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